Skip to content

Depression research published in 2025

Page 13 of 39: studies 241 to 260 of 761, newest first. Back to the depression overview

Studies

Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels.

ACS Chemical Neuroscience July 29, 2025 Lin Zhu, Ji Chen, Yuan Liu et al. 1 citation

This research focuses on the promising use of esketamine in perinatal depression, a widespread disorder impacting postpartum women's mental health. Despite esketamine's known rapid antidepressant effects, its precise mechanisms are not fully understood. This study integrates clinical and preclinical approaches to explore esketamine's efficacy in treating perinatal depression and its actions...

Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group.

Psychiatry Research July 26, 2025 Giacomo D’andrea, Clara Cavallotto, Mauro Pettorruso et al. 16 citations

INTRODUCTION Anhedonia, defined as the diminished ability to experience or anticipate pleasure, is a core symptom of major depressive disorder (MDD) and bipolar depression (BD), and associated with depression severity, suicidality and poor treatment outcomes. Conventional antidepressants demonstrate limited efficacy against anhedonia. Esketamine nasal spray (ESK-NS) - a novel NMDA receptor...

Beyond Anesthesia: Ketamine’s Expanding Role in Chronic Pain and Psychiatric Disorders

Journal of Integrative Neuroscience July 25, 2025 Christopher Zaki 1 citation

OBJECTIVE: This review explores ketamine's expanding role in managing both chronic pain and mental health conditions, focusing on its pharmacologic mechanisms, clinical applications, and therapeutic potential. We assess its analgesic properties, FDA-approved application in the form of Spravato (esketamine) for depression, and off-label use for analgesia and psychiatric disorders. METHODS: A...

Effectiveness of mindfulness-based cognitive therapy via e-health on anxiety and depression in adults: A meta-analysis.

General Hospital Psychiatry July 24, 2025 Shizhen Wang, Mengru Wu, Jixiang Wei et al. 6 citations

Anxiety and depression are highly prevalent mental health disorders, imposing significant burdens on individuals and healthcare systems. Mindfulness-based cognitive therapy (MBCT) has demonstrated effectiveness in reducing these symptoms. Electronic health MBCT (eMBCT) offers a scalable alternative, but its efficacy in alleviating anxiety and depression in adults remains unclear. To examine the...

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction July 24, 2025 Amandine Luquiens, Dahbia Belahda, Carine Graux et al. 22 citations

Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted psychotherapy for patients with comorbid...

DOI: 10.1111/add.70152 (opens in new tab) Alcohol use disorder Dual disorders Feasibility Psychedelics +14

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

Nature Medicine July 24, 2025 Luke A. Jelen, David J Lythgoe, James Stone et al. 29 citations

We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder. Twenty-six adults with major depressive disorder participated in a double-blind crossover study, receiving oral placebo or 50 mg naltrexone before an intravenous infusion of 0.5 mg per kg ketamine. Brain glutamatergic activity in the anterior...

DOI: 10.1038/s41591-025-03800-w (opens in new tab) Full text (opens in new tab) Ketamine Depression treatment Opioid system Mechanism of action

Differential effects of mindfulness and grit on positive mental health outcomes in major depressive and bipolar disorders: A moderation analysis using an ecological momentary assessment approach.

Journal of Affective Disorders July 23, 2025 Joyce Xu Hao Jin, Heidi Ka Ying Lo, Iris Wai Tung Tsui et al. 2 citations

Holistic management of persons living with Major Depressive Disorder (MDD) and Bipolar Disorder (BD) invites the need for evaluation of positive mental health (PMH; pleasure attainment and meaning-in-life), alongside conventional measures of psychopathology. The aforementioned dimensions of PMH involve aspects of mindfulness and grit. Herein, we evaluate these aspects using ecological momentary...

Effectiveness of Mindfulness-Based Stress Reduction on Salivary Cortisol and α-amylase Level, Anxiety and Depression in Students: A Randomized and Parallel-Group Clinical Trial.

Applied Psychophysiology and Biofeedback July 22, 2025 Saba Hassanvandi, Reza Mohammadzadegan, Seyed Hassan Saadat et al.

The current trial aimed to assess the effectiveness of Mindfulness-Based Stress Reduction training on salivary cortisol and α-amylase levels, anxiety and depression of students. This research was an experimental trial with a pre-test-post-test design and a control group. The statistical population of the research included all students studying in the universities of Khoy, Iran in 2021. The...

Radiation therapy patients' interest in psychedelic-assisted therapy: results of a survey.

Radiation oncology (London, England) July 21, 2025 Jino Park, Rufus Banks, Akul Munjal et al.

Comorbid mental health symptoms impact 30-40% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Among patients undergoing radiation therapy, which is delivered with palliative intent in nearly half of all cases and for those nearing end-of-life, these rates may be even higher. Emerging research underscores the promising potential of...

Pharmacokinetics, Safety, and Tolerability of (R)-Ketamine Hydrochloride Injection, a Novel Rapid-Acting Antidepressant, in Healthy Chinese Subjects.

Pharmaceuticals July 21, 2025 Rui Wang, Yuqian Yang, Tong Zhou et al.

Objectives: (R)-ketamine hydrochloride injection is a novel, rapid-acting antidepressant for the treatment of treatment-resistant depression. The aim of this study was to assess the pharmacokinetics, safety, and tolerability of (R)-ketamine hydrochloride injection in healthy Chinese subjects following ascending single intravenous doses ranging from 10.0 mg to 180 mg. Methods: This randomized,...

Perturbing whole‐brain models of brain hierarchy: An application for depression following pharmacological treatment

Annals of the New York Academy of Sciences July 21, 2025 Marcel Socoró-garrigosa, Yonatan Sanz Perl, Morten L. Kringelbach et al. 3 citations

Abstract Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally dominated, evidence suggests information is also encoded in distributed, hierarchical networks. Recent research indicates that the hierarchy of causal influences shaping functional patterns serves as a signature of distinct brain states, with...

Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression

Neuropsychopharmacology Reports July 20, 2025 Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek et al. 3 citations

OBJECTIVES: Ketamine is a prototypical rapid-acting antidepressant for treatment-resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response. This study explored features of ketamine nonresponse in TRBD. METHODS: In a post hoc analysis of a naturalistic study, 35 TRBD patients received a four-week ketamine regimen (intravenous 0.5 mg/kg or oral 2.0/2.5 mg/kg)....

Sex-Specific Neuropsychiatric Effects of Subanesthetic Ketamine Exposure in Pregnant Mice and Their Offspring.

Cellular and molecular neurobiology July 19, 2025 Wei-Sheng Lin, Pei-Yu Wang, Sheng-Rong Yeh et al.

Depression during pregnancy is often overlooked and undertreated. Ketamine has been shown to exert prompt and sustained antidepressant effects in patients with depression, although concerns of potential neurotoxicity prohibit its use in pregnant women. Here, we aim to investigate the neurobehavioral effects of subanesthetic ketamine on pregnant mice and their offspring. We found that pregnant...

Outcomes of patients receiving interventional psychiatric procedures in a large integrated healthcare system.

Psychiatry Research July 19, 2025 Kevin J Li, Natalie E Slama, Ingrid L Chen et al. 2 citations

Interventional psychiatric procedures (IPPs) such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine intravenous treatments (KIT) are widely used for treatment resistant depression (TRD), but we lack studies of their real-world impact compared to standard outpatient medication management (MM). Longitudinal electronic health records of 22,481 patients in a...

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression-A Pilot Study.

Pharmaceuticals July 19, 2025 Daniel Szawarnoga, Joanna Fojcik, Michał Górski et al. 1 citation

Background: Insomnia, as one of the most common sleep disorders, is a significant health problem, especially among patients suffering from drug-resistant depression. Problems related to the quality of sleep in that population can significantly affect the effectiveness of treatment and quality of life, which is why it is necessary to search for effective therapeutic interventions in this area....

Optimizing ketamine dosing strategies across diverse clinical applications: a comprehensive review.

Annals of Medicine and Surgery July 18, 2025 Ahmed M Kedwany, Reem Sayad, Nada S Jibril et al.

Ketamine has emerged as a versatile therapeutic agent with applications spanning anesthesia, pain management, and psychiatric disorders. This review examines ketamine's clinical utility across diverse administration routes, including intravenous, intramuscular, intranasal, and oral, emphasizing the need to individualize dosing regimens. We explore factors influencing ketamine dosing, such as...

The sustained effect of 5-week EmotionCore mindfulness training on emotion regulation and emotional intelligence: heterogeneous benefits for depression and anxiety across subgroups

Frontiers in Psychiatry July 18, 2025 Hui Kou, Wei Luo, Yiwei Wang et al. 2 citations

Background: The present study investigated the sustained effects of a 5-week EmotionCore mindfulness training program on emotion regulation, emotional intelligence (EI), trait mindfulness, depression, and anxiety among 120 undergraduates, while exploring the mediating mechanisms of training effect and heterogeneous effects across subgroups. Methods: Participants were randomly assigned to a...

Breath-Focused Mindfulness and Compassion Training in Parent-Child Dyads: Pilot Intervention Study.

JMIR Formative Research July 17, 2025 Satish Jaiswal, Jason Nan, Seth Dizon et al. 5 citations

Depression in children is a concerning societal issue and can be associated with poor academic performance, school dropout, and poor overall quality of life. Additionally, child depression is often associated with parallel stress and depression in parents. This scenario highlights the urgent need for the development and implementation of accessible and scalable solutions that may cobenefit...

The Causal Role of Consciousness in Psychedelic Therapy for Treatment-Resistant Depression: Hypothesis and Proposal

ACS Pharmacology & Translational Science July 16, 2025 Tobías Fernández-Borkel, Lucas F Borkel, Jaime Rojas-Hernández et al. 3 citations

The therapeutic potential of psychedelic substances, particularly psilocybin, for treatment-resistant depression (TRD) has garnered considerable attention. However, the necessity of subjective psychedelic experiences for therapeutic efficacy remains unclear, creating a critical gap in the field. To determine whether subjective psychedelic experiences induced by psilocybin are required for its...

DOI: 10.1021/acsptsci.5c00445 (opens in new tab) Consciousness Depression economics Psychotherapist Clinical psychology +2

Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.

Molecular Biology Reports July 16, 2025 Vida Mafikandi, Leila Hosseini, Fatemehsadat Seyedaghamiri et al.

Cerebrolysin (CBL), a peptide derived from pig brain, is recognized for its neuroprotective and anti-inflammatory properties. This research aimed to investigate the effects of CBL on anxiety- and depression-like behaviors, spatial memory, the tryptophan/kynurenine (TRP/KYN) pathway, and inflammation in the prefrontal cortex (PFC) of a mouse model for schizophrenia. Thirty-six male BALB/c mice...

DOI: 10.1007/s11033-025-10820-9 (opens in new tab) Full text (opens in new tab) Cognitive dysfunction Cerebrolysin: cerebrolysin Schizophrenia research: schizophrenia Model mimicking schizophrenia +7